Department of Pharmaceutical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China; Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu province, 210009, China.
Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu province, 210009, China.
Biomaterials. 2023 Nov;302:122319. doi: 10.1016/j.biomaterials.2023.122319. Epub 2023 Sep 11.
Cancer vaccine holds vast promise in potentiating tumor immunotherapy. Here, we developed a simple cancer vaccine based on the liquid nitrogen-treated cells (LNT cells) that engineered by one-shot shocking of the live tumor cells in liquid nitrogen. In this vaccine, the obtained LNT cells served as both tumor antigens and delivery vehicles to load the adjuvant imiquimod (R837). This design could achieve efficient co-uptake of antigen/adjuvant by antigen presenting cells (APCs) and prolong in vivo retention of tumor antigens and adjuvants. This adjuvant-loaded LNT cells augmented in vivo antitumor responses and enhanced survival in melanoma-bearing mouse model compared with conventional whole-cell vaccine of the mixture of tumor lysis and adjuvant.
癌症疫苗在增强肿瘤免疫治疗方面具有巨大的潜力。在这里,我们开发了一种基于液氮处理细胞(LNT 细胞)的简单癌症疫苗,该细胞是通过将活肿瘤细胞在液氮中一次性冲击而构建的。在这种疫苗中,获得的 LNT 细胞既作为肿瘤抗原,又作为载体来负载佐剂咪喹莫特(R837)。这种设计可以实现抗原呈递细胞(APC)对抗原/佐剂的有效共摄取,并延长体内肿瘤抗原和佐剂的保留时间。与肿瘤裂解物和佐剂混合物的常规全细胞疫苗相比,负载佐剂的 LNT 细胞增强了体内抗肿瘤反应,并提高了荷瘤小鼠模型的存活率。